Oppenheimer Upgrades Biogen (BIIB) Following Strong BG-12 Trial Data, Q1 Earnings
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $201.99 +4.56%
Rating Summary:
29 Buy, 13 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
29 Buy, 13 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
An analyst at Oppenheimer just upgraded shares of Biogen (NASDAQ: BIIB) from Underperform to Perform in a mid-day research note. The firm suspended its $62 price target.
Thursday's upgrade follows Q1 earnings from the company earlier. Additionally, and likely more importantly, Biogen announced strong results from a trial of its BG-12 multiple sclerosis pill.
Biogen shares last traded at $102.82, up 18.7 percent from Wednesday's closing price.
For more ratings news on Biogen click here and for the rating history of Biogen click here.
Thursday's upgrade follows Q1 earnings from the company earlier. Additionally, and likely more importantly, Biogen announced strong results from a trial of its BG-12 multiple sclerosis pill.
Biogen shares last traded at $102.82, up 18.7 percent from Wednesday's closing price.
For more ratings news on Biogen click here and for the rating history of Biogen click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) tops earnings expectations but revenue falls short
- Universal Health Realty (UHT) Reports Q1 EPS of $0.38
- First Bancorp. (FBNC) Misses Q1 EPS by 2c
Create E-mail Alert Related Categories
UpgradesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
